Looking forward to this new Meet the Professor in Thoracic Tumors virtual session! It will be a pleasure to have professor @peters_solange sharing the latest developments in thoracic oncology. Together with @EnriquetaFelip, we are delighted to have you join us on September 22!

An unfortunate development in a SCLC landscape where post-tarlatamab, few approved options. Would not read too much into the withdrawal - need to wait for phase III results as phase II likely inadequate. The B7-H3 class holds great promise with tam-peli, ris-rez, & I-DXd.

Me uno a los agradecimientos. ¡Felicidades, un año más, por la excelente organización y, sobre todo, por la magnífica acogida! 👏👏

🔵🗣️ ¡Vuelven los 'Diálogos @AEACaP'! ➡️ Esta edición contará con la participación de la doctora @NReguart 🗓️ 23 de septiembre 🕔 17.00 horas ➡️ ¡Resuelve todas tus dudas con la especialista! ℹ️ Inscríbete en 👉 bit.ly/AEACaP-dialogos-noemi…

🔵🫁 @AEACaP y el @HospitalJaen organizan la jornada '#Cáncerdepulmón: aprendiendo juntos' para hablar sobre 🔹 cuidarse forma parte del tratamiento 🔹 experiencias de pacientes 🗓️ 7 de octubre 🕓 16h 📍 @colmedjaen ℹ️ Inscríbete en 👉 bit.ly/aeacap-aprendiendo-ju…

🔵🫁¿Eres paciente o cuidador/a de una persona con #cáncerdepulmón? ➡️Queremos conocer la calidad de vida de las personas afectadas y el impacto que la enfermedad tiene en su vida diaria 📝Ayúdanos y responde a esta encuesta anónima de @LungCancerEu ℹ️ bit.ly/aeacap-encuesta-luce-…

Virtual Session on the Latest Developments in Thoracic Tumors - Noemi Reguart, MD, PhD @NReguart @peters_solange @EnriquetaFelip

Great timing for our new @JCO_ASCO review on PACC mutations & EGFR exon 20 insertions in NSCLC. “Uncommon EGFR” is no longer one disease , structure matters, and increasingly guides therapy. And #WCLC26 provided a perfect example: REZILIENT3 showed zipalertinib + chemo significantly improved PFS in 1L EGFR Ex20ins NSCLC: 14.5 vs 8.5 mo | HR 0.50 From molecular structure → rational drug development → Phase III evidence. Proud to be part of this review with a fantastic group of colleagues! @caliraf @LeXiuning @fede_monaca Dr Randulfe, Pr Heymach, Dr Zhou ascopubs.org/doi/10.1200/JCO… #LCSM #EGFR #NSCLC

🔵🗣️ ¡Vuelven los 'Diálogos @AEACaP'! ➡️ Esta edición contará con la participación de la doctora @NReguart 🗓️ 23 de septiembre 🕔 17.00 horas ➡️ ¡Resuelve todas tus dudas con la especialista! ℹ️ Inscríbete en 👉 bit.ly/AEACaP-dialogos-noemi…

📝 #JAMAReview: #LiquidBiopsy using circulating #tumor #DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy. Detectable circulating tumor DNA after curative-intent treatment was associated with recurrence and poorer survival across multiple cancer settings, often before progression was evident on imaging. ja.ma/4dFgtVU

As oncology continues to evolve, innovation alone is not enough. Evidence-based standards, classifications and frameworks are essential to support consistent implementation in #ClinicalPractice across health systems. ​🔗ow.ly/RnwY50ZOlAf ​ @FAndreMD

🔥HARMONi-2: "Statistically significant overall survival (OS) benefit" 🆙 @AkesoInc @SMMT_TX 🔜 #WCLC26 👥Patients: Locally advanced or metastatic, PD-L1-positive (TPS ≥1%), EGFR/ALK wild-type NSCLC, treatment-naïve 3⃣Phase III 🎯OS HR 0.73 (95% CI: 0.57, 0.95) 🎯mOS 30.8m vs 22.6m ⚖️Ivonescimab monotherapy ⚖️Pembrolizumab monotherapy 🔢NCT05499390 #LCSM @OncoAlert @Larvol 🔗 akesobio.com/en/media/akeso-… 🔗 smmttx.com/news/press-releas…

Happening right now! ES41 debate — should we convert the borderline resectable to resectable? ASEM Ballroom, Room 202 #WCLC26 @IASLC @jonas_willmann

Original Article: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy (phase 3 TAISHAN-302 trial) nej.md/4xKtvcF #WCLC26 | @IASLC

👉 Free for ESMO members: Essentials for Clinicians: Thoracic Tumours - a ‘must read’ for all professionals working in #lungcancer. 🔗 Download your copy here: ow.ly/TtP850ZL8sw A huge thank you to all authors and editors for their contribution. #ESMOBooks #WCLC26

Explaining at the "Initiation and plasticity" session of #WCLC2026 @IASLC that a significant fraction of cancer of unknown primary #CUP are occult non-small cell #lung #cancer #NSCLC

🔥Simultaneous JTO publication🔥

😳 Disappointing results of T-DXd in large randomized phase III Destiny-Lung04 first line in HER2mut NSCLC vs SoC chemo-pembro. Although control arm outperformed, the lack of translation into OS benefit and the concerning safety issues of this agent warrants a lot of discussion, specially in the upcoming data from selective HER2 TKIs, with are associated with better tolerance and safety profile. #WCLC26 @iasclc #lcsm

DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetrexed in HER2-mutant NSCLC: 14.3 vs 8.3 mo | HR 0.63 (95% CI 0.50–0.79), P<0.0001. IA No OS benefit. Of note considerable ILD (overall 20.8%, 2% Gr 5).@JuliaRotow #HER2 #NSCLC #LCSM

Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR! #WCLC26 ‼️measurable CNS Mets n=10, IC-ORR 100% - Tox similar to other ROS1 TKIs. ⭐️Another efficacious option joins Taletrectinib!